	US 11,890,302 B2
	Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains
Agapitos Patakas, Holytown Motherwell (GB); Timothy London, Holytown Motherwell (GB); and Emilio Cosimo, Holytown Motherwell (GB)
Assigned to TC BIOPHARM LIMITED, Holytown Motherwell (GB)
Appl. No. 16/649,982
Filed by TC Biopharm Limited, Holytown Motherwell (GB)
PCT Filed Oct. 1, 2018, PCT No. PCT/GB2018/052801 § 371(c)(1), (2) Date Mar. 24, 2020, PCT Pub. No. WO2019/064030, PCT Pub. Date Apr. 4, 2019.
Claims priority of application No. 1715918 (GB), filed on Sep. 29, 2017.
Prior Publication US 2020/0289564 A1, Sep. 17, 2020
Int. Cl. A61K 35/17 (2015.01); C07K 14/735 (2006.01); C12N 15/86 (2006.01)

CPC A61K 35/17 (2013.01) [C07K 14/70535 (2013.01); C12N 15/86 (2013.01); C07K 2319/03 (2013.01); C12N 2740/15043 (2013.01)]

7 Claims

1. A gamma delta T cell comprising a nucleic acid construct to provide for expression of a CAR comprising:

(i) an antigen-binding domain coupled to a trans-membrane domain, and

(ii) an intracellular activation signalling domain

wherein the intracellular signalling domain consists of one or more Fcγ Receptor intracellular signalling domains, wherein the one or more Fcγ Receptor intracellular signalling domains is from an Fc R common gamma chain, a CD16, a CD32a, a CD32c, or a CD64, and wherein binding of antigen to the antigen binding domain of the CAR causes signalling by the intracellular signalling domain of the CAR.